Additionally, a study designed to prevent SCLC transformation is combining platinum–etoposide chemotherapy plus osimertinib in the first-line setting for EGFR-mutated NSCLC with concurrent RB1 and TP53 mutations (NCT03567642). This evidence concerns the gene EGFR and non-small cell lung carcinoma.